NCT02477878 2022-07-12
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
Bellicum Pharmaceuticals
Phase 1 Active not recruiting
Bellicum Pharmaceuticals
National Institutes of Health Clinical Center (CC)
Bellicum Pharmaceuticals